BOCA RATON, FL--(Marketwired - March 19, 2015) - Vascular Pathways, Inc., a privately held medical device manufacturer with innovative wire-guided technology for peripheral intravascular access, today announced they have received FDA 510(k) clearance for the AccuCath® Midline Catheter System. With a 3.1 inch catheter, Blood Control features, and Patented AccuTip™ coiled tip Nitinol Guidewire, the AccuCath® 3.1" BC Midline Catheter is designed as a new option for patients with challenged peripheral vasculature.
"Our new AccuCath® 3.1" BC Midline Catheter provides a clinical solution to DIVA (Difficult IV Access) patients whose stay will last 29 days or less and don't require a central line," said Bill Bold., President and CEO. "It's ergonomic design, increased length, and patented coiled-tip Nitinol guidewire are designed to access vasculature previously considered too deep for traditional IV placement."
The AccuCath® 3.1" BC Midline Catheter integrates a coiled tip Nitinol guidewire, blood control valve, and needlestick safety features with a 3.1 inch power injectable catheter for use with Ultrasound devices on hard-stick and patients with challenged peripheral vasculature. Its design is intended to increase first attempt success, reduce complication rates, extend dwell times, increase patient satisfaction, and lower overall costs to the provider. The AccuCath® 3.1" BC Midline Catheter will be available in the US in April 2015.
About Vascular Pathways, Inc.
Founded in 2005, by Amir Belson, M.D., Vascular Pathways is a medical device company commercializing the AccuCath® IV Catheter System line, an FDA cleared, guidewire catheter system enabling rapid, safe, and successful intravascular insertion. Vascular Pathways, Inc. is privately held by CHL Medical Partners, Ascension Health Ventures, and MVM Life Sciences. For further information about Vascular Pathways or the AccuCath® Catheter System line, please visit http://www.vascularpathways.com or call 844-VASPATH.